Isoplexis Corp., of Branford, Conn., which focuses on advancing single-cell biomarkers in oncology, said it raised $25 million in series C funding led by Northpond Ventures and including new and current investors Spring Mountain Capital, Ironwood Capital, North Sound Capital and Connecticut Innovations.